These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 27494570)

  • 1. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
    Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-month multicenter, randomized study comparing the levonorgestrel intrauterine system with the etonogestrel subdermal implant.
    Apter D; Briggs P; Tuppurainen M; Grunert J; Lukkari-Lax E; Rybowski S; Gemzell-Danielsson K
    Fertil Steril; 2016 Jul; 106(1):151-157.e5. PubMed ID: 27016644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.
    Gemzell-Danielsson K; Apter D; Hauck B; Schmelter T; Rybowski S; Rosen K; Nelson A
    PLoS One; 2015; 10(9):e0135309. PubMed ID: 26378938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-arm phase III study exploring the efficacy and safety of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5 mg), in an Asia-Pacific population.
    Fan G; Kang S; Ren M; Weisberg E; Lukkari-Lax E; Roth K; Shin S
    Contraception; 2017 Apr; 95(4):371-377. PubMed ID: 27913229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of a new, low-dose levonorgestrel intrauterine contraceptive system over 5 years of use.
    Gemzell-Danielsson K; Apter D; Dermout S; Faustmann T; Rosen K; Schmelter T; Merz M; Nelson A
    Eur J Obstet Gynecol Reprod Biol; 2017 Mar; 210():22-28. PubMed ID: 27930941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
    Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
    Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
    Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
    Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and impact on quality of life of different drug treatments after partial resection of rectovaginal endometriosis].
    Li T; Xu XX; Dai Y; Zhang JJ; Lang JH; Leng JH
    Zhonghua Fu Chan Ke Za Zhi; 2017 May; 52(5):307-313. PubMed ID: 28545268
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia.
    Endrikat J; Shapiro H; Lukkari-Lax E; Kunz M; Schmidt W; Fortier M
    J Obstet Gynaecol Can; 2009 Apr; 31(4):340-347. PubMed ID: 19497153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomised clinical trial to assess satisfaction with the levonorgestrel- releasing intrauterine system inserted at caesarean section compared to postpartum placement.
    Braniff K; Gomez E; Muller R
    Aust N Z J Obstet Gynaecol; 2015 Jun; 55(3):279-83. PubMed ID: 26053465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives.
    Modesto W; Bahamondes MV; Bahamondes L
    Hum Reprod; 2014 Jul; 29(7):1393-9. PubMed ID: 24812309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
    Bilgehan F; Dilbaz B; Karadag B; Deveci CD
    J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual function and quality of life of women adopting the levonorgestrel-releasing intrauterine system (LNG-IUS 13.5 mg) after abortion for unintended pregnancy.
    Caruso S; Cianci S; Vitale SG; Fava V; Cutello S; Cianci A
    Eur J Contracept Reprod Health Care; 2018 Feb; 23(1):24-31. PubMed ID: 29436865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal and intrauterine methods for contraception for women aged 25 years and younger.
    Krashin J; Tang JH; Mody S; Lopez LM
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD009805. PubMed ID: 26280888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of a 5-year contraceptive trial in parous and nulliparous women with a new LNG-IUS.
    Wildemeersch D; Goldstuck ND; Jackers G
    Gynecol Endocrinol; 2017 Mar; 33(3):223-226. PubMed ID: 28084114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.